Needham & Company LLC Cuts Cooper Companies (NASDAQ:COO) Price Target to $73.00

Cooper Companies (NASDAQ:COO) had its target price decreased by Needham & Company LLC from $86.00 to $73.00 in a research report released on Thursday morning, Marketbeat reports. Needham & Company LLC currently has a buy rating on the medical device company’s stock.

Several other equities research analysts have also recently weighed in on the stock. UBS Group initiated coverage on shares of Cooper Companies in a research report on Tuesday, July 28th. They set a “neutral” rating and a $75.00 price objective for the company. JPMorgan Chase & Co. decreased their target price on shares of Cooper Companies from $80.00 to $71.00 and set a “neutral” rating on the stock in a report on Friday, June 5th. Stifel Nicolaus decreased their target price on shares of Cooper Companies from $95.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, June 5th. Wall Street Zen upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating in a research report on Sunday, June 21st. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Cooper Companies in a report on Friday, September 4th. Five research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $71.47.

Cooper Companies Price Performance

Shares of NASDAQ COO opened at $53.91 on Thursday. The business has a fifty day moving average price of $71.62 and a two-hundred day moving average price of $69.70. The stock has a market capitalization of $10.25 billion, a PE ratio of 18.40, a P/E/G ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.78. Cooper Companies has a fifty-two week low of $51.01 and a fifty-two week high of $89.83.

Cooper Companies (NASDAQ:COO) last released its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.12 by $0.03. The company had revenue of $1.07 billion for the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.Cooper Companies’s quarterly revenue was up .5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.49 EPS. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, equities analysts predict that Cooper Companies will post 4.53 earnings per share for the current fiscal year.

Cooper Companies declared that its Board of Directors has initiated a share repurchase program on Wednesday, September 9th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the medical device company to reacquire up to 22.7% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Institutional Trading of Cooper Companies

Hedge funds and other institutional investors have recently made changes to their positions in the company. Avalon Trust Co acquired a new position in shares of Cooper Companies in the second quarter valued at approximately $25,000. Root Financial Partners LLC raised its holdings in Cooper Companies by 104.5% in the 4th quarter. Root Financial Partners LLC now owns 317 shares of the medical device company’s stock valued at $26,000 after buying an additional 162 shares during the last quarter. SJS Investment Consulting Inc. boosted its position in Cooper Companies by 107.5% during the 1st quarter. SJS Investment Consulting Inc. now owns 361 shares of the medical device company’s stock worth $26,000 after buying an additional 187 shares during the period. Elevation Wealth Partners LLC boosted its position in Cooper Companies by 1,136.4% during the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock worth $29,000 after buying an additional 375 shares during the period. Finally, Continuum Advisory LLC bought a new stake in Cooper Companies during the 2nd quarter worth approximately $30,000. 24.39% of the stock is currently owned by institutional investors.

Trending Headlines about Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper reported adjusted fiscal Q3 earnings of $1.15 per share, ahead of the approximately $1.11–$1.12 consensus, with earnings up from $0.49 a year earlier. Cost controls and continued fertility-related growth helped offset weakness elsewhere. Cooper Companies Bets on Fertility Growth Despite Weakness in CooperVision
• Positive Sentiment: The board authorized an additional $1 billion of repurchases, bringing the total buyback authorization to $3 billion. The program could support per-share earnings and signal management believes COO shares are undervalued. Cooper Outlines Q4 EPS and Adds to Buyback Authorization
• Neutral Sentiment: Cooper completed a strategic review but chose not to pursue a sale or separate transaction for CooperSurgical. Keeping the business preserves its fertility-growth opportunity, but investors had apparently anticipated a potential deal or value-unlocking action. Cooper Cos. Stock Drops After Soft Outlook and No Deal
• Negative Sentiment: Revenue rose only about 1% to $1.066 billion, missing the roughly $1.10 billion consensus. U.S. channel destocking and inventory reductions pressured CooperVision, raising concerns about near-term demand and sales momentum. COO Q3 Earnings Top Estimates, Revenues Miss on Destocking
• Negative Sentiment: Management reduced fiscal 2026 earnings guidance to $4.51–$4.55 per share and issued fourth-quarter guidance of $1.05–$1.09, below prior expectations. The weaker outlook triggered multiple analyst downgrades and price-target cuts, including from Baird, UBS, JPMorgan and William Blair.
• Negative Sentiment: Law firms have announced securities-fraud investigations connected with the post-earnings decline. These notices are often promotional, but they add to negative investor sentiment and potential legal uncertainty. Securities Fraud Investigation Into Cooper Companies Announced

About Cooper Companies

Cooper Companies, Inc is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company develops, manufactures and markets products through two primary business segments: CooperVision and CooperSurgical.

CooperVision specializes in contact lenses, including daily disposable, toric, multifocal, multifocal toric, specialty and myopia-management lenses. Its products are designed to address a range of vision-correction needs, including astigmatism, presbyopia and irregular corneas.